<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7270404</article-id><article-id pub-id-type="doi">10.3389/fimmu.2020.01229</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sallenave</surname><given-names>Jean-Michel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/516687/overview"/></contrib><contrib contrib-type="author"><name><surname>Guillot</surname><given-names>Lo&#x000ef;c</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/412584/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>INSERM UMR1152, Laboratoire d'Excellence Inflamex, Facult&#x000e9; de M&#x000e9;decine, H&#x000f4;pital Bichat, Universit&#x000e9; de Paris</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff2"><sup>2</sup><institution>Sorbonne Universit&#x000e9;, INSERM UMR S 938, Centre de Recherche Saint-Antoine (CRSA)</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Gennady Bocharov, Institute of Numerical Mathematics (RAS), Russia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Fran&#x000e7;ois J. M. A. Meurens, Agroalimentaire et de l'alimentation de Nantes-Atlantique, France; Simon H. Bridge, Northumbria University, United Kingdom</p></fn><corresp id="c001">*Correspondence: Jean-Michel Sallenave <email>jean-michel.sallenave@inserm.fr</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>28</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>28</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>11</volume><elocation-id>1229</elocation-id><history><date date-type="received"><day>10</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 Sallenave and Guillot.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Sallenave and Guillot</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>COVID-19 is caused by the Severe Acute Respiratory Syndrome (SARS) coronavirus (Cov)-2, an enveloped virus with a positive-polarity, single-stranded RNA genome. The initial outbreak of the pandemic began in December 2019, and it is affecting the human health of the global community. In common with previous pandemics (Influenza H1N1 and SARS-CoV) and the epidemics of Middle east respiratory syndrome (MERS)-CoV, CoVs target bronchial and alveolar epithelial cells. Virus protein ligands (e.g., haemagglutinin or trimeric spike glycoprotein for Influenza and CoV, respectively) interact with cellular receptors, such as (depending on the virus) either sialic acids, Dipeptidyl peptidase 4 (DPP4), or angiotensin-converting enzyme 2 (ACE2). Host proteases, e.g., cathepsins, furin, or members of the type II transmembrane serine proteases (TTSP) family, such as Transmembrane protease serine 2 (TMPRSS2), are involved in virus entry by proteolytically activating virus ligands. Also involved are Toll Like Receptor (TLR) family members, which upregulate anti-viral and pro-inflammatory mediators [interleukin (IL)-6 and IL-8 and type I and type III Interferons among others], through the activation of Nuclear Factor (NF)-kB. When these events (virus cellular entry and innate immune responses) are uncontrolled, a deleterious systemic response is sometimes encountered in infected patients, leading to the well-described &#x0201c;cytokine storm&#x0201d; and an ensuing multiple organ failure promoted by a downregulation of dendritic cell, macrophage, and T-cell function. We aim to describe how the lung and systemic host innate immune responses affect survival either positively, through downregulating initial viral load, or negatively, by triggering uncontrolled inflammation. An emphasis will be put on host cellular signaling pathways and proteases involved with a view on tackling these therapeutically.</p></abstract><kwd-group><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>coronavirus</kwd><kwd>protease</kwd><kwd>lung innate immunity</kwd></kwd-group><counts><fig-count count="2"/><table-count count="0"/><equation-count count="0"/><ref-count count="100"/><page-count count="9"/><word-count count="7463"/></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>COVID-19 is a respiratory disease whose aetiologic agent is a novel beta coronavirus (CoV) called Severe Acute Respiratory Syndrome (SARS)-CoV-2/2019-nCov. The initial outbreak of the pandemic began in December 2019, and it is currently affecting the health and safety of the global community. Indeed, on May 12, 2020, 4.5 million worldwide cases were confirmed (probably a significant under-estimation given the number of untested asymptomatic subjects), with a death toll exceeding 286,000. Before the SARS-CoV-2 outbreak, two related highly pathogenic CoVs viruses, Middle east respiratory syndrome (MERS)-CoV (<xref rid="B1" ref-type="bibr">1</xref>) and SARS-CoV (<xref rid="B2" ref-type="bibr">2</xref>), provoked catastrophic epidemics and pandemics, respectively. Unfortunately, no drugs nor vaccines have currently been approved to prevent or treat these viral episodes. The first anatomical/histological reports from the lungs of severely SARS-CoV-2-affected patients experiencing acute respiratory disease syndrome (ARDS) revealed excessive inflammatory activation and destruction of the bronchial and alveolar epithelium, features already observed during the first SARS pandemics in 2003 (<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>). Indeed, in the latter pandemic, lung alveolar epithelial cells were identified as the most likely site of virus replication, and it was suggested that alveolar macrophages may be responsible for the dissemination of viruses within the lungs (<xref rid="B3" ref-type="bibr">3</xref>). In accordance, initial histological analyses of lung biopsies from patients positive for SARS-CoV-2 have shown exfoliation of the bronchial epithelium, which may induce altered mucociliary clearance and affect host immune responses (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Indeed, there is no doubt that the latter are involved in modulating disease onset and progression. For example, early studies report that, similarly with what was observed with SARS-CoV, lymphopenia [sometimes equivalent or more severe than that observed in human immunodeficiency virus (HIV) infection] is often observed in severely affected patients progressing to ARDS. Despite, or maybe correlated with this, aberrant non-effective innate immune host responses seem associated with severe lung disease during SARS (<xref rid="B6" ref-type="bibr">6</xref>&#x02013;<xref rid="B12" ref-type="bibr">12</xref>).</p><p>The following sections will give an overview of the molecular and cellular mechanisms underpinning SARS-CoV virus infections and how lung and systemic host innate immune responses affect survival either positively, through downregulating the initial viral load, or negatively, by triggering uncontrolled inflammation. A particular emphasis will be put on the description of the host cellular signaling pathways and proteases involved with a view on tackling these therapeutically.</p></sec><sec id="s2"><title>Mechanisms of Entry of Coronaviruses into Target Epithelial Cells (SEE <xref ref-type="fig" rid="F1">FIGURE 1A</xref>)</title><p>CoVs are enveloped viruses with a positive-polarity, single-stranded RNA genome encoding four structural proteins: the transmembrane trimeric spike glycoprotein (S, composed of two subunits S1 and S2), envelop (E), matrix (M), and nucleocapsid (N) (<xref rid="B13" ref-type="bibr">13</xref>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Schematic representation of airway and lung infection by SARS-CoV-2 at early time points <bold>(A)</bold> and during SARS <bold>(B)</bold>. <bold>(A)</bold> The airway epithelium is composed of various cell types including ciliated (C), basal (B), glandular (G), and club cells (CC). It is covered by mucus (M) involved in the mucociliary clearance. Distal to the lung, the alveoli include alveolar type I (ATI) and type II (ATII) cells coated with surfactant (S). The airways are also protected by the resident alveolar macrophages (AM) and dendritic cells (DC). Through the action of host proteases, including the TTSP Transmembrane protease, serine 2 (TMPRSS2), and the interaction of SARS-CoV-2 with its cellular receptor angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 can enter and replicate into airway epithelial cells and AM. Also, interaction of the SARS-CoV-2 with the PRRs is instrumental in inducing cytokine, chemokine, and interferon responses for the establishment of innate and adaptive immune responses. <bold>(B)</bold> During SARS, innate immune responses are exacerbated in the alveolar space, with accumulation of activated monocytes (mono), activated macrophages (AM), interstitial macrophages (IM), and neutrophils (neut), leading to dysregulated inflammation, disruption of the alveolar-capillary membrane and tissue damage.</p></caption><graphic xlink:href="fimmu-11-01229-g0001"/></fig><p>The entry of CoV viruses into host epithelial cells is mediated by the interaction between the viral envelope S protein homotrimers and the cell surface receptors. Following proteolytic cleavage of the CoV S protein (&#x0201c;priming&#x0201d;), the S1 ecto-domain recognizes a membrane receptor [angiotensin-converting enzyme 2 (ACE2) for SARS-Cov and SARS-Cov-2 as well as Dipeptidyl peptidase 4 (DPP4) for MERS-Cov], whereas the S2 C-terminal domain is involved in cell fusion and viral entry (<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>). This mechanism of action is very similar to that used by <italic>Influenza</italic>, except that the latter use sialic acids as the cognate receptor for its hemagglutinin (HA) ligand. Importantly, many viruses (<italic>Influenza</italic>, MERS, CoV, and Paramyxoviruses such as Hendra and Nipah viruses) use similar host proteolytic enzymes for cleaving their ligands (HA and S), namely, mostly lysosomal (Cathepsins B, L), furin, or trypsin-like proteases (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>). Indeed, it is believed that it is the cellular source of these proteases that may determine the infectivity spectrum of these viruses, with the lung and the gastro-intestinal tract being high producers (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>).</p><p>Although a variety of these proteases have been studied and shown to be involved to varying degrees in virus activation, including neutrophil elastase (<xref rid="B21" ref-type="bibr">21</xref>), proteases of the type II transmembrane serine proteases (TTSP) family [HAT, Transmembrane protease, serine (TMPRSS)2, and TMPRSS4] have recently been demonstrated to be particularly important, albeit probably at different stages of the virus cell cycle (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B23" ref-type="bibr">23</xref>). In particular, recent research on SARS-Cov-2 has focused on TMPRSS2 and has shown it to be important (although mostly using cell lines infected with pseudotyped virus particles bearing SARS-Cov-2 S protein) for virus entry (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). In that context, it has also been demonstrated that the serine protease inhibitor camostat (see also below section on Therapeutic targets and Conclusion) was protective (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). In contrast, DPP4 which is necessary for the entry of MERS-CoV (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>) is not involved in SARS-Cov-2 entry (<xref rid="B24" ref-type="bibr">24</xref>). Unlike other SARS-CoVs, the S protein of SARS-CoV-2 has a furin cleavage site at the boundary between the S1 and S2 subunits, which is processed during biogenesis and which may explain CoV-2 high infectivity (<xref rid="B28" ref-type="bibr">28</xref>). Although mechanistic studies are obviously still in their infancy, it is very likely that SARS-CoV and SARS-CoV-2 target mainly respiratory epithelial cells with similar mechanisms. Indeed, as indicated above, initial work has shown that ACE2 is the S receptor for both SARS-CoV (<xref rid="B29" ref-type="bibr">29</xref>) and SARS-CoV-2 viruses (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>), and structural studies using cryo-electron microscopy suggest a binding of two S protein trimer to an ACE2 dimer (<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>).</p><p>Whether this is strictly dependent on ACE2/protease expression is debatable since ACE2 is present in other tissues in humans [such as the intestine, kidney, and testis (<xref rid="B31" ref-type="bibr">31</xref>)]. Indeed, &#x0201c;seasonal&#x0201d; low pathogenic CoVs (e.g., CoV-229E, CoV-OC43) infect mostly upper airways, whereas pathogenic CoVs (SARS-CoV/SARS-CoV-2 and MERS) have a tropism for the distal lung and can cause severe pneumonia and ARDS (<xref rid="B32" ref-type="bibr">32</xref>), as currently demonstrated again in the present pandemic. Indeed, potentially explaining this is the fact that seasonal coronaviruses do not use ACE2 as a receptor. <italic>In vitro</italic>, primary nasal and tracheobronchial epithelial cells as well as the Calu-3 bronchial cell line were shown to express ACE2 (the latter not colocalizing with cilia), and their infection with SARS-CoV was shown to be highly cytotoxic (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). In the distal lung, as hinted above, primary alveolar type II epithelial (ATII) cells are also permissive to SARS-CoV infection (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). SARS-CoV-2 has also been shown to infect various respiratory epithelial cell lines including A549 (alveolar origin), BEAS2-B (bronchial origin), Calu-3 cells, as well as primary human bronchial epithelial cells (<xref rid="B24" ref-type="bibr">24</xref>). Besides the lung, ACE2 is also highly expressed in the intestine (<xref rid="B37" ref-type="bibr">37</xref>), and gastrointestinal symptoms have been recorded with COVID-19 (<xref rid="B38" ref-type="bibr">38</xref>). It was shown that SARS-COV2 is able to infect enterocytes as well as intestinal organoids and induces a viral response characterized by the expression of mediators related to type I and III IFN (<xref rid="B39" ref-type="bibr">39</xref>).</p><p>Even if SARS-CoV2 is thought to originate from bats, the intermediate host between bats and humans is still unknown. SARS-CoV was previously shown to infect various wild and domestic animals, including cats, ferrets and pigs (<xref rid="B40" ref-type="bibr">40</xref>&#x02013;<xref rid="B42" ref-type="bibr">42</xref>). Similarly, recent work reveals that domestic animals, including ferrets and cats, are permissive to SARS-CoV-2 infection. In contrast, the virus replicates poorly in pigs, ducks, chickens, and dogs (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>Given the described importance of host proteases in mediating infectivity of a number of viruses, it is no surprise that, upon virus infection, murine knock-out (KO) for some of these molecules has shown some protection. For example, TMPRSS2-KO mice were protected from pulmonary disease and death following H1N1 and H7N9 <italic>Influenza</italic> infection, but not from that of the influenza H3N2 subtype, demonstrating some specificity and showing also that other TTSP proteases [such as DESC1 (TMPRSS11E) and MSPL (TMPRSS13)] or other factors may be important (<xref rid="B44" ref-type="bibr">44</xref>&#x02013;<xref rid="B47" ref-type="bibr">47</xref>).</p><p>Similarly, TMPRSS2 KO mice showed reduced body weight and viral loads compared to WT mice in animals infected with SARS-CoV (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>Also, it was demonstrated that over-expression of the human DPP4 in mice promoted MERS-CoV infection, causing lethal disease (<xref rid="B49" ref-type="bibr">49</xref>), and that TMPRSS2 was instrumental in that context (<xref rid="B48" ref-type="bibr">48</xref>).</p></sec><sec id="s3"><title>Activation/Modulation of Host Signaling Pathways (SEE <xref ref-type="fig" rid="F1">FIGURE 1A</xref>)</title><sec><title>Epithelial Cells</title><p>The control of viral infection requires an optimal and innate coordinated host antiviral immunity. This response is activated by various sensors, including pattern recognition receptors (PRR), which recognize pathogen-associated molecular patterns (PAMPs). Although for many viruses, viral RNA is a PAMP classically detected by different sensors, including Toll-Like Receptors (TLR)3 (which senses double stranded (ds)RNA), TLR7 and TLR8 [which sense single stranded (ss)RNA], RIG-I (which senses short dsRNA and ssRNA specific motifs), and MDA-5 (which senses long dsRNA) (<xref rid="B50" ref-type="bibr">50</xref>), the sensors potentially recognizing SARS-CoV genomic material are still elusive. In addition, although, as mentioned above, distal peripheral lung alveolar epithelial cells seem to harbor SARS-CoV infection <italic>in vivo</italic>, and although respiratory epithelial cells are known to express TLR3, TLR7, and TLR8 (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>) and initiate innate immunity in the lung (<xref rid="B53" ref-type="bibr">53</xref>), the study of these cells in anti-CoV responses has been hampered by their general poor permissibility to the virus <italic>in vitro</italic> (except for intestinal Caco-2 and HEK293 kidney epithelial cells) (<xref rid="B54" ref-type="bibr">54</xref>). In that respect, although the specific PRR involved was not identified, the M protein of SARS-CoV was indeed shown to induce interferon (IFN)-&#x003b2; in a TLR-related-TRAF3-independent mechanism in HEK293 cells (<xref rid="B55" ref-type="bibr">55</xref>). Regarding the lung, the differentiated Calu-3 cell line [when cultured at the air-liquid interface (ALI)] is the model of choice: in that set-up, SARS-CoV infection triggered an inflammatory response characterized by increased production of interleukin (IL)-6, IL-8, gamma interferon (IFN-&#x003b3;), inducible protein 10 (IP-10), and activation of the transcription factor NF-&#x003ba;B (<xref rid="B56" ref-type="bibr">56</xref>). However, the kinetics of this response was extremely slow, and importantly, type I IFN, an important mediator of anti-viral responses, was undetected.</p><p>Also, another study involving A549 cells demonstrated that the trimeric spike S glyprotein and virus-like particles were able to modestly upregulate CCL2, an important monocytic chemokine (<xref rid="B57" ref-type="bibr">57</xref>).</p><p>In addition to lung epithelial cells cultured at ALI, precision-cut lung slices could also be an interesting tool to study SARS-CoV2-cells interactions (<xref rid="B58" ref-type="bibr">58</xref>), as demonstrated in Influenza infections with human (<xref rid="B59" ref-type="bibr">59</xref>) or animal-derived material (<xref rid="B60" ref-type="bibr">60</xref>).</p><p>As mentioned above, TTSPs can activate virus-ligands (HA and S protein), but they are also able to modulate cell signaling pathways. For example, recombinant HAT is able to activate mucin gene expression in NCI-H292 lung epithelial cells (<xref rid="B61" ref-type="bibr">61</xref>). Relatedly, we have shown both <italic>in vitro</italic> in epithelial cells and in a murine model that <italic>Influenza H3N2</italic> is able to upregulate mucin expression and that this is dependent on human (or mouse) HAT upregulation and TACE activity (<xref rid="B62" ref-type="bibr">62</xref>). Interestingly, Haga et al. have shown that inhibiting TACE prevents SARS-CoV cellular entry (<xref rid="B63" ref-type="bibr">63</xref>). Strengthening the signaling potential of the receptors, Iwata-Yoshikawa et al. demonstrated <italic>in vivo</italic> that poly IC (TLR3 ligand) induces the expression of a variety of pro-inflammatory mediators (CCL2, KC, and IL-1) through the expression of TMPRSS2 (<xref rid="B48" ref-type="bibr">48</xref>).</p><p>In addition, although unclear as whether it is beneficial or detrimental to the host cell, SARS-CoV have been shown to activate host stress response, apoptosis, and autophagy (<xref rid="B13" ref-type="bibr">13</xref>). These are also various pathways that may also need to be evaluated therapeutically in the context of the current pandemic. Relatedly, we have shown that chloroquine, which also inhibits the autophagic cellular flux by decreasing autophagosome-lysosome fusion, can inhibit Influenza-mediated CCL5 production (<xref rid="B64" ref-type="bibr">64</xref>).</p><p>Importantly, after having established a foothold in the epithelial compartment, SARS-CoV can disrupt the epithelial polarity, thereby getting access to the parenchyma tissue: for example, it has been shown that the virus membrane protein E binds to PALS1 (Protein Associated With Lin Seven 1), a junction protein involved in epithelial polarity, and modifies its cellular distribution at the surface of HEK-293 cells (<xref rid="B65" ref-type="bibr">65</xref>).</p></sec><sec><title>Myeloid Cells and Myeloid-Epithelial Cells Interaction</title><p>Myeloid cells, e.g., alveolar and interstitial macrophages or dendritic cells (DCs), elicit different immune responses toward influenza viruses, according to their subtypes (<xref rid="B66" ref-type="bibr">66</xref>). It is thus predictable that specificities may also exist with respect to SARS-COV-2 infections. Indeed, although studies are scant, these cells have generally been shown to be poorly permissive to SARS-CoV replication (<xref rid="B54" ref-type="bibr">54</xref>, <xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>).</p><p>However, a few studies have shown that myeloid cells can respond to SARS-Cov infection. Indeed, Dosch et al. showed that the S protein could, through TLR2, trigger NF-&#x003ba;B activation and inflammatory responses in peripheral blood mononuclear cells (PBMC) (<xref rid="B69" ref-type="bibr">69</xref>). Also, in common with epithelial cells, it was shown that PBMCs and DCs infected with SARS-CoV produced cytokines and chemokines such as and C-C Motif Chemokine Ligand (CCL)-2 and/or C-X-C Motif Chemokine Ligand (CXCL)-10/RANTES/Tumor Necrosis Factor (TNF)/IL-8/IL-6, but, importantly, not IFN-&#x003b2; (<xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>). By contrast, a study performed mostly on THP-1 macrophages suggest that MERS S protein suppresses macrophages pro-inflammatory responses through DPP4-induction of IRAK-M and PPAR&#x003b3; (<xref rid="B70" ref-type="bibr">70</xref>).</p><p>Furthermore, in an interesting &#x0201c;2-way&#x0201d; system involving differentiated SARS-permissive lung Calu-3 cells and monocyte-derived Macs and DCs, it was shown that mediators produced by Calu-3 cells activate cytokine production by macrophages (IL-1&#x003b2;, G-CSF, MIP-1, and TNF-&#x003b1;) and DCs (IL-12p40, MIP-1, IFN-&#x003b3;, IL-6, IL-8, and MCP-1) but that some of these Calu-3 derived mediators (in particular IL-6 and IL-8) compromised the ability of DCs and Macs to activate na&#x000ef;ve T cells and phagocytosis (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B56" ref-type="bibr">56</xref>). This echoes data obtained from patients suggesting that SARS may in fact be partly caused by a &#x0201c;paralysis&#x0201d; of the adaptive immune system, characterized by a diminished number of immune cell types including T lymphocytes, DCs and Macs (<xref rid="B4" ref-type="bibr">4</xref>).</p></sec><sec><title>From Murine Models to Human Genetics</title><p>Demonstrating that SARS-CoV can induce TLR-dependent host responses <italic>in vivo, Tlr4, Tlr3</italic>, and <italic>Tram</italic> KO mice were shown to be more susceptible to mouse-adapted SARS-CoV, albeit without exhibiting extra mortality (<xref rid="B71" ref-type="bibr">71</xref>). In comparison, mice deficient for the signaling molecule <italic>Trif</italic> were highly susceptible to CoV infections, exhibited diminished lung function, aberrant inflammatory responses, and importantly, higher mortality (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>In addition, a mouse genetic study revealed that the TLR adaptor protein <italic>Ticam2</italic> was a susceptibility gene to SARS-CoV (<xref rid="B72" ref-type="bibr">72</xref>); mice KO for <italic>Ticam2</italic> (<xref rid="B72" ref-type="bibr">72</xref>), but also <italic>MyD88</italic> (<xref rid="B73" ref-type="bibr">73</xref>), another TLR adaptor protein, were highly susceptible to a mouse-adapted SARS-CoV lung infection. Since polymorphisms of TLRs and MyD88 have been associated in humans with heightened sensitivity to a variety of pathogens (<xref rid="B74" ref-type="bibr">74</xref>), these studies, in addition to demonstrating the role of TLR pathways in the SARS-CoV infection, suggested a human genetic predisposition to SARS-CoV, and this could explain the variability of severity in patients with COVID-19 disease. Forthcoming human genetic studies from international collaborative efforts (<ext-link ext-link-type="uri" xlink:href="https://www.covid19hg.org">https://www.covid19hg.org</ext-link>) could reveal genetic variants associated with SARS-CoV2 susceptibility, as in the gene encoding ACE2 as recently suggested (<xref rid="B75" ref-type="bibr">75</xref>). Indeed, <italic>ACE2</italic> genetic variants may be associated with a modulated ACE2 protein expression, the SARS-Cov-2 receptor, which may explain in part patients' susceptibility to infection. Genes associated with TLR pathways also represent good candidates, as demonstrated in other respiratory viral infection (e.g., influenza) where <italic>TLR3</italic> variants (<xref rid="B76" ref-type="bibr">76</xref>) were shown to modulate its virulence.</p></sec><sec><title>Maladaptive Activation of Innate Immune Responses (see <xref ref-type="fig" rid="F1">Figure 1B</xref>)</title><p>As already mentioned above, aberrant maladaptive innate immune host responses, including &#x0201c;cytokine storm&#x0201d; events, have been associated with severe lung disease and the development of ARDS during SARS and the COVID-19 current episode. Mechanistically, these events usually occur at a late stage of the disease, and several mechanisms have been proposed. In particular, a murine study has shown that a prolonged (albeit delayed, as demonstrated also <italic>in vitro</italic>, see above) type I IFN signaling was instrumental in triggering over-exuberant innate inflammatory monocytes&#x02013;macrophages immune responses and an impaired virus-specific T-cell response (<xref rid="B77" ref-type="bibr">77</xref>).</p><p>In complement to the mechanism proposed above, increased lung inflammatory protease (neutrophil elastase and metalloprotease) activity has been demonstrated in ARDS (<xref rid="B78" ref-type="bibr">78</xref>, <xref rid="B79" ref-type="bibr">79</xref>), with a concomitant imbalance between protease and protease inhibitors activity (<xref rid="B80" ref-type="bibr">80</xref>). In addition, although not yet measured, to our knowledge, in SARS murine models, we and others have shown increased protease-mediated lung damage in mice infected with <italic>Influenza</italic> (<xref rid="B81" ref-type="bibr">81</xref>&#x02013;<xref rid="B83" ref-type="bibr">83</xref>). Additionally, in a MERS-CoV murine model, it was shown that excessive complement activation was partly responsible for exacerbated lung inflammation (<xref rid="B84" ref-type="bibr">84</xref>).</p><p>Lastly, &#x0201c;cytokines storm&#x0201d; may also results from SOCS (suppressors of cytokine signaling) inhibition (<xref rid="B85" ref-type="bibr">85</xref>). Indeed, upon Influenza infection, SOCS1 and SOCS3 were shown to reduce type I IFN antiviral responses in human bronchial epithelial cells (<xref rid="B86" ref-type="bibr">86</xref>). Also, SOCS4-deficient mice exhibited heightened sensitivity to Influenza infection (<xref rid="B87" ref-type="bibr">87</xref>). Studies about SOCS involvement during coronavirus infections are currently lacking and should therefore bring new interesting information.</p></sec></sec><sec id="s4"><title>Potential Therapeutic Targets and Conclusion (See <xref ref-type="fig" rid="F2">FIGURE 2</xref>)</title><p>On May 12, 2020, using the term &#x0201c;COVID,&#x0201d; an unbiased search of already registered trials on <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link> retrieved 1,409 hits, and, when refined with &#x0201c;double blind/placebo,&#x0201d; 119 hits were found. Although the number of trials that are ongoing or &#x0201c;under recruitment&#x0201d; is expectedly very high, the range of molecules tested is relatively narrow and aimed at targeting mainly antivirals. These include remdesivir (21 hits), lopinavir/ritonavir (also used in AIDS), as well as interferons (46 hits). Also falling in that category are trials testing molecules aiming to block viral entry at the cellular surface by targeting ACE-inhibitors (32 hits) or the membrane proteases of the TTSP family (see above) using camostat mesilate (5 hits). Repurposing of non-antiviral drugs may offer new promising options, such as with Ivermectin&#x02014;an FDA-approved anti-parasitic drug widely available and recently shown to inhibit SARS-CoV-2 <italic>in vitro</italic> (<xref rid="B88" ref-type="bibr">88</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Prophylactic/therapeutic approaches to COVID-19. <bold>(A)</bold> Potential therapeutic anti-viral approaches during the early phase of infection. <bold>(B)</bold> Potential anti-inflammatory strategies targeting the alveolar space during the SARS period of COVID disease. <bold>(C)</bold> Immune intervention (vaccination of the population prior to epidemic episodes) or use of convalescent plasma/hyper-immune globulins on infected patients. LYM: lymphocytes; other acronyms are as described in <xref ref-type="fig" rid="F1">Figure 1</xref>.</p></caption><graphic xlink:href="fimmu-11-01229-g0002"/></fig><p>Because the virus load is not necessarily correlated with symptoms deterioration in SARS (the latter being often caused by worsening of inflammation at day 7&#x02013;10 post onset of clinical signs), it follows that anti-inflammatory drugs could/should be prescribed during that stage of the disease (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>In that context, &#x0201c;classical&#x0201d; anti-inflammatory drugs are indeed currently being tested against COVID-19 [e.g., methylprednisolone, budesonide, hydrocortisone, azithromycin, and non-stero&#x000ef;dal anti-inflammatory drugs (NSAIDs)]. In addition, more specific agents are also being investigated, targeting either IL-&#x003b2; (anakinra, 13 hits), IL-6 signaling (Siltuximab/3 hits, Tocilizumab/42 hits, Sarilumab/13 hits), or CD24 (CD24Fc) with the main objective to modulate the &#x0201c;cytokine storm.&#x0201d;</p><p>However, chloroquine/hydroxychloroquine has, so far, undoubtedly taken the lion's share (178 hits), and it has attracted a lot of media attention. In that respect, the results from an initial pan-European endeavor (&#x0201c;Discovery&#x0201d;), now conducted largely in France because of enrollment difficulties, are eagerly awaited. This drug has a &#x0201c;mixed&#x0201d; mode of action. Indeed, it acts as an anti-viral (presumably through inhibition of lysosomal enzymes requiring an acidic pH and of activation of endolysosomes, see above section &#x0201c;Mechanisms of entry&#x0201d;) and as an anti-inflammatory molecule, and it has notably been used in inflammatory rheumatic diseases (<xref rid="B89" ref-type="bibr">89</xref>). Despite a relative safe profile, having been administered to millions of people over the years, worries have nevertheless arisen about cardiac issues in many individuals with severe Covid-19, and this will have to be properly assessed (<xref rid="B90" ref-type="bibr">90</xref>).</p><p>Regardless, the ultimate prize in the fight against COVID-19 (or further SARS-CoV infections) undoubtedly lies with the future generation of effective vaccines and the development of neutralizing antibodies (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B92" ref-type="bibr">92</xref>).</p><p>Unfortunately, coronavirus vaccines in general have attracted less attention compared to the effort dedicated to vaccines against other potential pandemic viruses such as Influenza. For example, from 2012 onwards, few SARS-CoV vaccines reached phase 1 clinical trials for lack of interest from the pharmaceutical industry when it became evident that the virus was not making a &#x0201c;comeback&#x0201d; after its initial appearance. However, although probably too late for affecting the current &#x0201c;first wave&#x0201d; of SARS-CoV-2 pandemic, many pharmaceutical companies and research laboratories are now working on a plethora of vaccine formulations [for a review, see (<xref rid="B91" ref-type="bibr">91</xref>) and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">https://clinicaltrials.gov</ext-link>, the latter reporting so far 83 clinical trials on vaccines].</p><p>Indeed, in pre-clinical studies, the determination of cryo-EM structures of the SARS-CoV-2 S ectodomain trimer is providing a blueprint for the design of vaccines and inhibitors of viral entry (<xref rid="B28" ref-type="bibr">28</xref>). In this context, promising results show that murine polyclonal antibodies against S protein of SARS-CoV are able to elicit polyclonal antibody responses, preventing SARS-CoV-2 entry into cells, and thus indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination (<xref rid="B28" ref-type="bibr">28</xref>).</p><p>In addition to testing the best SARS-CoV-2 specific epitopes from the most suitable proteins (S, N, etc.) and way of administration (best vectors, etc.), it is important to select the best animal models. Although convincing murine studies are still pending, as indicated above in the section &#x0201c;Mechanisms of entry&#x02026;&#x0201d;, studies in other animals investigated the virus susceptibility of chickens, ducks, dogs, pigs, cats, and ferrets, with the latter two being the most permissive (<xref rid="B43" ref-type="bibr">43</xref>). Further up in the phylogenetic scale, a recent study reported that an inactivated vaccine candidate for SARS-CoV-2 was protective in macaques (<xref rid="B93" ref-type="bibr">93</xref>).</p><p>Finally, large epidemiological studies have demonstrated that Bacille Calmette-Guerin (BCG) can heterologously protect against virus infections [e.g., yellow fever virus (<xref rid="B94" ref-type="bibr">94</xref>), probably by tapping on trained immunity mechanisms (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>)]. Using such adjuvant-mediated strategies against SARS-CoV viruses may therefore be an exciting avenue worthwhile pursuing (<xref rid="B97" ref-type="bibr">97</xref>&#x02013;<xref rid="B99" ref-type="bibr">99</xref>).</p></sec><sec id="s5"><title>Author Contributions</title><p>All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.</p></sec><sec id="s6"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><ack><p>LG and J-MS received grants from the Facult&#x000e9; de M&#x000e9;decine Sorbonne Universit&#x000e9; (AAP COVID19 and Universit&#x000e9; de Paris (Fonds d'urgence SARS-CoV-2 et COVID-19), respectively. This manuscript has been released as a pre-print at OSF (<xref rid="B100" ref-type="bibr">100</xref>).</p></ack><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chafekar</surname><given-names>A</given-names></name><name><surname>Fielding</surname><given-names>BC</given-names></name></person-group>. <article-title>MERS-CoV: understanding the latest human coronavirus threat</article-title>. <source>Viruses.</source> (<year>2018</year>) <volume>10</volume>:<fpage>93</fpage>. <pub-id pub-id-type="doi">10.20944/preprints201711.0198.v2</pub-id><?supplied-pmid 29495250?><pub-id pub-id-type="pmid">29495250</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><name><surname>Osterhaus</surname><given-names>AD</given-names></name><name><surname>Stohr</surname><given-names>K</given-names></name></person-group>. <article-title>The severe acute respiratory syndrome</article-title>. <source>N Engl J Med.</source> (<year>2003</year>) <volume>349</volume>:<fpage>2431</fpage>&#x02013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra032498</pub-id><?supplied-pmid 14681510?><pub-id pub-id-type="pmid">14681510</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicholls</surname><given-names>JM</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Lee</surname><given-names>KC</given-names></name><name><surname>Ng</surname><given-names>WF</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Leung</surname><given-names>CY</given-names></name><etal/></person-group>. <article-title>Lung pathology of fatal severe acute respiratory syndrome</article-title>. <source>Lancet.</source> (<year>2003</year>) <volume>361</volume>:<fpage>1773</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13413-7</pub-id><?supplied-pmid 12781536?><pub-id pub-id-type="pmid">12781536</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Multiple organ infection and the pathogenesis of SARS</article-title>. <source>J Exp Med.</source> (<year>2005</year>) <volume>202</volume>:<fpage>415</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20050828</pub-id><?supplied-pmid 16043521?><pub-id pub-id-type="pmid">16043521</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>XH</given-names></name><name><surname>Li</surname><given-names>TY</given-names></name><name><surname>He</surname><given-names>ZC</given-names></name><name><surname>Ping</surname><given-names>YF</given-names></name><name><surname>Liu</surname><given-names>HW</given-names></name><name><surname>Yu</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>[A pathological report of three COVID-19 cases by minimally invasive autopsies]</article-title>. <source>Zhonghua Bing Li Xue Za Zhi.</source> (<year>2020</year>) <volume>49</volume>:<fpage>411</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.cn112151-20200312-00193</pub-id><?supplied-pmid 32172546?><pub-id pub-id-type="pmid">32172546</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Clinical and immunologic features in severe and moderate Coronavirus Disease 2019</article-title>. <source>J Clin Invest.</source> (<year>2020</year>) <volume>130</volume>:<fpage>2620</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1172/JCI137244</pub-id><?supplied-pmid 32217835?><pub-id pub-id-type="pmid">32217835</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giamarellos-Bourboulis</surname><given-names>EJ</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Rovina</surname><given-names>N</given-names></name><name><surname>Akinosoglou</surname><given-names>K</given-names></name><name><surname>Antoniadou</surname><given-names>A</given-names></name><name><surname>Antonakos</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Complex immune dysregulation in COVID-19 patients with severe respiratory failure</article-title>. <source>Cell Host Microbe</source>. (<year>2020</year>) <pub-id pub-id-type="doi">10.1016/j.chom.2020.04.009</pub-id>. [Epub ahead of print].<?supplied-pmid 32320677?><pub-id pub-id-type="pmid">32320677</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet.</source> (<year>2020</year>) <volume>395</volume>:<fpage>497</fpage>&#x02013;<lpage>506</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id><?supplied-pmid 31986264?><pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lescure</surname><given-names>FX</given-names></name><name><surname>Bouadma</surname><given-names>L</given-names></name><name><surname>Nguyen</surname><given-names>D</given-names></name><name><surname>Parisey</surname><given-names>M</given-names></name><name><surname>Wicky</surname><given-names>PH</given-names></name><name><surname>Behillil</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Clinical and virological data of the first cases of COVID-19 in Europe: a case series</article-title>. <source>Lancet Infect Dis.</source> (<year>2020</year>) <volume>20</volume>:<fpage>697</fpage>&#x02013;<lpage>706</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30200-0</pub-id><?supplied-pmid 32224310?><pub-id pub-id-type="pmid">32224310</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thevarajan</surname><given-names>I</given-names></name><name><surname>Nguyen</surname><given-names>THO</given-names></name><name><surname>Koutsakos</surname><given-names>M</given-names></name><name><surname>Druce</surname><given-names>J</given-names></name><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>van de Sandt</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19</article-title>. <source>Nat. Med.</source> (<year>2020</year>) <volume>26</volume>:<fpage>453</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-020-0819-2</pub-id><?supplied-pmid 32284614?><pub-id pub-id-type="pmid">32284614</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Cai</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus Disease 2019 pneumonia in Wuhan, China</article-title>. <source>JAMA Intern Med</source>. (<year>2020</year>). <pub-id pub-id-type="doi">10.1001/jamainternmed.2020.0994</pub-id>. [Epub ahead of print].<?supplied-pmid 32167524?><pub-id pub-id-type="pmid">32167524</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Yang</surname><given-names>XP</given-names></name><etal/></person-group>. <article-title>Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients</article-title>. <source>Cell Mol Immunol.</source> (<year>2020</year>) <volume>17</volume>:<fpage>541</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0401-3</pub-id><?supplied-pmid 32203186?><pub-id pub-id-type="pmid">32203186</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fung</surname><given-names>TS</given-names></name><name><surname>Liu</surname><given-names>DX</given-names></name></person-group>
<article-title>Human coronavirus: host-pathogen interaction</article-title>. <source>Annu Rev Microbiol.</source> (<year>2019</year>) <volume>73</volume>:<fpage>529</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-micro-020518-115759</pub-id><pub-id pub-id-type="pmid">31226023</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millet</surname><given-names>JK</given-names></name><name><surname>Whittaker</surname><given-names>GR</given-names></name></person-group>. <article-title>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis</article-title>. <source>Virus Res.</source> (<year>2015</year>) <volume>202</volume>:<fpage>120</fpage>&#x02013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2014.11.021</pub-id><?supplied-pmid 25445340?><pub-id pub-id-type="pmid">25445340</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group>. <article-title>Structural insights into coronavirus entry</article-title>. <source>Adv Virus Res.</source> (<year>2019</year>) <volume>105</volume>:<fpage>93</fpage>&#x02013;<lpage>116</lpage>. <pub-id pub-id-type="doi">10.1016/bs.aivir.2019.08.002</pub-id><?supplied-pmid 31522710?><pub-id pub-id-type="pmid">31522710</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B</given-names></name><name><surname>Valle</surname><given-names>C</given-names></name><name><surname>de Lamballerie</surname><given-names>X</given-names></name><name><surname>Canard</surname><given-names>B</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Decroly</surname><given-names>E</given-names></name></person-group>. <article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title>. <source>Antiviral Res.</source> (<year>2020</year>) <volume>176</volume>:<fpage>104742</fpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104742</pub-id><?supplied-pmid 32057769?><pub-id pub-id-type="pmid">32057769</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugge</surname><given-names>TH</given-names></name><name><surname>Antalis</surname><given-names>TM</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name></person-group>. <article-title>Type II transmembrane serine proteases</article-title>. <source>J Biol Chem.</source> (<year>2009</year>) <volume>284</volume>:<fpage>23177</fpage>&#x02013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.R109.021006</pub-id><?supplied-pmid 19487698?><pub-id pub-id-type="pmid">19487698</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>SY</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Park</surname><given-names>YW</given-names></name><name><surname>Pohlmann</surname><given-names>S</given-names></name></person-group>. <article-title>Type II transmembrane serine proteases in cancer and viral infections</article-title>. <source>Trends Mol Med.</source> (<year>2009</year>) <volume>15</volume>:<fpage>303</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.molmed.2009.05.003</pub-id><?supplied-pmid 19581128?><pub-id pub-id-type="pmid">19581128</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottcher-Friebertshauser</surname><given-names>E</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Garten</surname><given-names>W</given-names></name></person-group>. <article-title>Activation of influenza viruses by proteases from host cells and bacteria in the human airway epithelium</article-title>. <source>Pathog Dis.</source> (<year>2013</year>) <volume>69</volume>:<fpage>87</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1111/2049-632X.12053</pub-id><?supplied-pmid 23821437?><pub-id pub-id-type="pmid">23821437</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garten</surname><given-names>W</given-names></name><name><surname>Braden</surname><given-names>C</given-names></name><name><surname>Arendt</surname><given-names>A</given-names></name><name><surname>Peitsch</surname><given-names>C</given-names></name><name><surname>Baron</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Influenza virus activating host proteases: identification, localization and inhibitors as potential therapeutics</article-title>. <source>Eur J Cell Biol.</source> (<year>2015</year>) <volume>94</volume>:<fpage>375</fpage>&#x02013;<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejcb.2015.05.013</pub-id><?supplied-pmid 26095298?><pub-id pub-id-type="pmid">26095298</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Ujike</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>S</given-names></name><name><surname>Tashiro</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>F</given-names></name></person-group>. <article-title>Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2005</year>) <volume>102</volume>:<fpage>12543</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0503203102</pub-id><?supplied-pmid 16116101?><pub-id pub-id-type="pmid">16116101</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bottcher</surname><given-names>E</given-names></name><name><surname>Matrosovich</surname><given-names>T</given-names></name><name><surname>Beyerle</surname><given-names>M</given-names></name><name><surname>Klenk</surname><given-names>HD</given-names></name><name><surname>Garten</surname><given-names>W</given-names></name><name><surname>Matrosovich</surname><given-names>M</given-names></name></person-group>. <article-title>Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium</article-title>. <source>J Virol.</source> (<year>2006</year>) <volume>80</volume>:<fpage>9896</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01118-06</pub-id><?supplied-pmid 16973594?><pub-id pub-id-type="pmid">16973594</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Glowacka</surname><given-names>I</given-names></name><name><surname>Muller</surname><given-names>MA</given-names></name><name><surname>Lavender</surname><given-names>H</given-names></name><name><surname>Gnirss</surname><given-names>K</given-names></name><name><surname>Nehlmeier</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease</article-title>. <source>J Virol.</source> (<year>2011</year>) <volume>85</volume>:<fpage>13363</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.05300-11</pub-id><?supplied-pmid 21994442?><pub-id pub-id-type="pmid">21994442</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kruger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>80</lpage>.e8. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><?supplied-pmid 32142651?><pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S</given-names></name><name><surname>Nao</surname><given-names>N</given-names></name><name><surname>Shirato</surname><given-names>K</given-names></name><name><surname>Kawase</surname><given-names>M</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Takayama</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2020</year>) <volume>117</volume>:<fpage>7001</fpage>&#x02013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.2002589117</pub-id><?supplied-pmid 32165541?><pub-id pub-id-type="pmid">32165541</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title>. <source>Nature.</source> (<year>2013</year>) <volume>500</volume>:<fpage>227</fpage>&#x02013;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1038/nature12328</pub-id><?supplied-pmid 23831647?><pub-id pub-id-type="pmid">23831647</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>VS</given-names></name><name><surname>Mou</surname><given-names>H</given-names></name><name><surname>Smits</surname><given-names>SL</given-names></name><name><surname>Dekkers</surname><given-names>DH</given-names></name><name><surname>Muller</surname><given-names>MA</given-names></name><name><surname>Dijkman</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title>. <source>Nature.</source> (<year>2013</year>) <volume>495</volume>:<fpage>251</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1038/nature12005</pub-id><?supplied-pmid 23486063?><pub-id pub-id-type="pmid">23486063</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walls</surname><given-names>AC</given-names></name><name><surname>Park</surname><given-names>YJ</given-names></name><name><surname>Tortorici</surname><given-names>MA</given-names></name><name><surname>Wall</surname><given-names>A</given-names></name><name><surname>McGuire</surname><given-names>AT</given-names></name><name><surname>Veesler</surname><given-names>D</given-names></name></person-group>. <article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell.</source> (<year>2020</year>) <volume>181</volume>:<fpage>281</fpage>&#x02013;<lpage>92</lpage>.e6. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id><?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title>. <source>Nat Med.</source> (<year>2005</year>) <volume>11</volume>:<fpage>875</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nm1267</pub-id><?supplied-pmid 16007097?><pub-id pub-id-type="pmid">16007097</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group>. <article-title>Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2</article-title>. <source>Science.</source> (<year>2020</year>) <volume>367</volume>:<fpage>1444</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.abb2762</pub-id><?supplied-pmid 32132184?><pub-id pub-id-type="pmid">32132184</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I</given-names></name><name><surname>Timens</surname><given-names>W</given-names></name><name><surname>Bulthuis</surname><given-names>ML</given-names></name><name><surname>Lely</surname><given-names>AT</given-names></name><name><surname>Navis</surname><given-names>G</given-names></name><name><surname>van Goor</surname><given-names>H</given-names></name></person-group>. <article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title>. <source>J Pathol.</source> (<year>2004</year>) <volume>203</volume>:<fpage>631</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1002/path.1570</pub-id><?supplied-pmid 15141377?><pub-id pub-id-type="pmid">15141377</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name></person-group>. <article-title>Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology</article-title>. <source>Semin Immunopathol.</source> (<year>2017</year>) <volume>39</volume>:<fpage>529</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-017-0629-x</pub-id><?supplied-pmid 28466096?><pub-id pub-id-type="pmid">28466096</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Burkett</surname><given-names>SE</given-names></name><name><surname>Collins</surname><given-names>PL</given-names></name><name><surname>Pickles</surname><given-names>RJ</given-names></name></person-group>. <article-title>Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>15511</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.24.15511-15524.2005</pub-id><?supplied-pmid 16306622?><pub-id pub-id-type="pmid">16306622</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Burkett</surname><given-names>SE</given-names></name><name><surname>Yount</surname><given-names>B</given-names></name><name><surname>Pickles</surname><given-names>RJ</given-names></name></person-group>
<article-title>SARS-CoV replication and pathogenesis in an <italic>in vitro</italic> model of the human conducting airway epithelium</article-title>. <source>Virus Res.</source> (<year>2008</year>) <volume>133</volume>:<fpage>33</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.013</pub-id><pub-id pub-id-type="pmid">17451829</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mossel</surname><given-names>EC</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jeffers</surname><given-names>S</given-names></name><name><surname>Edeen</surname><given-names>KE</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Cosgrove</surname><given-names>GP</given-names></name><etal/></person-group>. <article-title>SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells</article-title>. <source>Virology.</source> (<year>2008</year>) <volume>372</volume>:<fpage>127</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2007.09.045</pub-id><?supplied-pmid 18022664?><pub-id pub-id-type="pmid">18022664</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Travanty</surname><given-names>EA</given-names></name><name><surname>Oko</surname><given-names>L</given-names></name><name><surname>Edeen</surname><given-names>K</given-names></name><name><surname>Berglund</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Innate immune response of human alveolar type II cells infected with severe acute respiratory syndrome-coronavirus</article-title>. <source>Am J Respir Cell Mol Biol.</source> (<year>2013</year>) <volume>48</volume>:<fpage>742</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2012-0339OC</pub-id><?supplied-pmid 23418343?><pub-id pub-id-type="pmid">23418343</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmer</surname><given-names>D</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Borman</surname><given-names>R</given-names></name><name><surname>Clark</surname><given-names>KL</given-names></name></person-group>. <article-title>Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme</article-title>. <source>FEBS Lett.</source> (<year>2002</year>) <volume>532</volume>:<fpage>107</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-5793(02)03640-2</pub-id><?supplied-pmid 12459472?><pub-id pub-id-type="pmid">12459472</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group>. <article-title>COVID-19: gastrointestinal manifestations and potential fecal-oral transmission</article-title>. <source>Gastroenterology.</source> (<year>2020</year>) <volume>158</volume>:<fpage>1518</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.02.054</pub-id><?supplied-pmid 32142785?><pub-id pub-id-type="pmid">32142785</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>MM</given-names></name><name><surname>Beumer</surname><given-names>J</given-names></name><name><surname>van der Vaart</surname><given-names>J</given-names></name><name><surname>Knoops</surname><given-names>K</given-names></name><name><surname>Puschhof</surname><given-names>J</given-names></name><name><surname>Breugem</surname><given-names>TI</given-names></name><etal/></person-group>. <article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title>. <source>Science.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id>. [Epub ahead of print].<?supplied-pmid 32358202?><pub-id pub-id-type="pmid">32358202</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>BJ</given-names></name><name><surname>He</surname><given-names>YQ</given-names></name><name><surname>Liu</surname><given-names>XL</given-names></name><name><surname>Zhuang</surname><given-names>ZX</given-names></name><name><surname>Cheung</surname><given-names>CL</given-names></name><etal/></person-group>. <article-title>Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China</article-title>. <source>Science.</source> (<year>2003</year>) <volume>302</volume>:<fpage>276</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.1087139</pub-id><?supplied-pmid 12958366?><pub-id pub-id-type="pmid">12958366</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martina</surname><given-names>BE</given-names></name><name><surname>Haagmans</surname><given-names>BL</given-names></name><name><surname>Kuiken</surname><given-names>T</given-names></name><name><surname>Fouchier</surname><given-names>RA</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><name><surname>Van Amerongen</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Virology: SARS virus infection of cats and ferrets</article-title>. <source>Nature.</source> (<year>2003</year>) <volume>425</volume>:<fpage>915</fpage>. <pub-id pub-id-type="doi">10.1038/425915a</pub-id><?supplied-pmid 14586458?><pub-id pub-id-type="pmid">14586458</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>SARS-associated coronavirus transmitted from human to pig</article-title>. <source>Emerg Infect Dis.</source> (<year>2005</year>) <volume>11</volume>:<fpage>446</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3201/eid1103.040824</pub-id><?supplied-pmid 15757562?><pub-id pub-id-type="pmid">15757562</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wen</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2</article-title>. <source>Science.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1126/science.abb7015</pub-id>. [Epub ahead of print].<?supplied-pmid 32269068?><pub-id pub-id-type="pmid">32269068</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatesuer</surname><given-names>B</given-names></name><name><surname>Bertram</surname><given-names>S</given-names></name><name><surname>Mehnert</surname><given-names>N</given-names></name><name><surname>Bahgat</surname><given-names>MM</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Pohlmann</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Tmprss2 is essential for influenza H1N1 virus pathogenesis in mice</article-title>. <source>PLoS Pathog.</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003774</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003774</pub-id><?supplied-pmid 24348248?><pub-id pub-id-type="pmid">24348248</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Ami</surname><given-names>Y</given-names></name><name><surname>Tahara</surname><given-names>M</given-names></name><name><surname>Kubota</surname><given-names>T</given-names></name><name><surname>Anraku</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The host protease TMPRSS2 plays a major role in <italic>in vivo</italic> replication of emerging H7N9 and seasonal influenza viruses</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>5608</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03677-13</pub-id><?supplied-pmid 24600012?><pub-id pub-id-type="pmid">24600012</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarnow</surname><given-names>C</given-names></name><name><surname>Engels</surname><given-names>G</given-names></name><name><surname>Arendt</surname><given-names>A</given-names></name><name><surname>Schwalm</surname><given-names>F</given-names></name><name><surname>Sediri</surname><given-names>H</given-names></name><name><surname>Preuss</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>4744</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03799-13</pub-id><?supplied-pmid 24522916?><pub-id pub-id-type="pmid">24522916</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zmora</surname><given-names>P</given-names></name><name><surname>Blazejewska</surname><given-names>P</given-names></name><name><surname>Moldenhauer</surname><given-names>AS</given-names></name><name><surname>Welsch</surname><given-names>K</given-names></name><name><surname>Nehlmeier</surname><given-names>I</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>12087</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01427-14</pub-id><?supplied-pmid 25122802?><pub-id pub-id-type="pmid">25122802</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Hasegawa</surname><given-names>H</given-names></name><name><surname>Takeda</surname><given-names>M</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name></person-group>. <article-title>TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection</article-title>. <source>J Virol.</source> (<year>2019</year>) <volume>93</volume>:<fpage>e01815</fpage>-<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01815-18</pub-id><?supplied-pmid 30626688?><pub-id pub-id-type="pmid">30626688</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Wohlford-Lenane</surname><given-names>CL</given-names></name><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Park</surname><given-names>JE</given-names></name><name><surname>Earnest</surname><given-names>JT</given-names></name><name><surname>Bair</surname><given-names>TB</given-names></name><etal/></person-group>. <article-title>Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>2017</year>) <volume>114</volume>:<fpage>E3119</fpage>&#x02013;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1619109114</pub-id><?supplied-pmid 28348219?><pub-id pub-id-type="pmid">28348219</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>KT</given-names></name><name><surname>Gale</surname><given-names>MJr</given-names></name><name><surname>Loo</surname><given-names>YM</given-names></name></person-group>. <article-title>RIG-I and Other RNA Sensors in antiviral immunity</article-title>. <source>Annu Rev Immunol.</source> (<year>2018</year>) <volume>36</volume>:<fpage>667</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053309</pub-id><?supplied-pmid 29677479?><pub-id pub-id-type="pmid">29677479</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillot</surname><given-names>L</given-names></name><name><surname>Le Goffic</surname><given-names>R</given-names></name><name><surname>Bloch</surname><given-names>S</given-names></name><name><surname>Escriou</surname><given-names>N</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Chignard</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus</article-title>. <source>J Biol Chem.</source> (<year>2005</year>) <volume>280</volume>:<fpage>5571</fpage>&#x02013;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M410592200</pub-id><?supplied-pmid 15579900?><pub-id pub-id-type="pmid">15579900</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ioannidis</surname><given-names>I</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>McNally</surname><given-names>B</given-names></name><name><surname>Willette</surname><given-names>M</given-names></name><name><surname>Flano</surname><given-names>E</given-names></name></person-group>. <article-title>Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells</article-title>. <source>J Virol.</source> (<year>2013</year>) <volume>87</volume>:<fpage>3261</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01956-12</pub-id><?supplied-pmid 23302870?><pub-id pub-id-type="pmid">23302870</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitsett</surname><given-names>JA</given-names></name><name><surname>Alenghat</surname><given-names>T</given-names></name></person-group>. <article-title>Respiratory epithelial cells orchestrate pulmonary innate immunity</article-title>. <source>Nat Immunol.</source> (<year>2015</year>) <volume>16</volume>:<fpage>27</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/ni.3045</pub-id><?supplied-pmid 25521682?><pub-id pub-id-type="pmid">25521682</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name></person-group>. <article-title>SARS coronavirus and innate immunity</article-title>. <source>Virus Res.</source> (<year>2008</year>) <volume>133</volume>:<fpage>101</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2007.03.015</pub-id><?supplied-pmid 17451827?><pub-id pub-id-type="pmid">17451827</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name></person-group>. <article-title>The membrane protein of severe acute respiratory syndrome coronavirus functions as a novel cytosolic pathogen-associated molecular pattern to promote beta interferon induction via a toll-like-receptor-related TRAF3-independent mechanism</article-title>. <source>MBio.</source> (<year>2016</year>) <volume>7</volume>:<fpage>e01872</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.01872-15</pub-id><?supplied-pmid 26861016?><pub-id pub-id-type="pmid">26861016</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshikawa</surname><given-names>T</given-names></name><name><surname>Hill</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Peters</surname><given-names>CJ</given-names></name><name><surname>Tseng</surname><given-names>CT</given-names></name></person-group>. <article-title>Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells</article-title>. <source>J Virol.</source> (<year>2009</year>) <volume>83</volume>:<fpage>3039</fpage>&#x02013;<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.01792-08</pub-id><?supplied-pmid 19004938?><pub-id pub-id-type="pmid">19004938</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>IY</given-names></name><name><surname>Chang</surname><given-names>SC</given-names></name><name><surname>Wu</surname><given-names>HY</given-names></name><name><surname>Yu</surname><given-names>TC</given-names></name><name><surname>Wei</surname><given-names>WC</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway</article-title>. <source>J Virol.</source> (<year>2010</year>) <volume>84</volume>:<fpage>7703</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02560-09</pub-id><?supplied-pmid 20484496?><pub-id pub-id-type="pmid">20484496</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsafadi</surname><given-names>HN</given-names></name><name><surname>Uhl</surname><given-names>FE</given-names></name><name><surname>Pineda</surname><given-names>RH</given-names></name><name><surname>Bailey</surname><given-names>KE</given-names></name><name><surname>Rojas</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>DE</given-names></name><etal/></person-group>. <article-title>Applications and approaches for 3D precision-cut lung slices: disease modeling and drug discovery</article-title>. <source>Am J Respir Cell Mol Biol.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1165/rcmb.2019-0276TR</pub-id>. [Epub ahead of print].<?supplied-pmid 31991090?><pub-id pub-id-type="pmid">31991090</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Booth</surname><given-names>JL</given-names></name><name><surname>Duggan</surname><given-names>ES</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>KB</given-names></name><name><surname>Coggeshall</surname><given-names>KM</given-names></name><etal/></person-group>. <article-title>Innate immune response to H3N2 and H1N1 influenza virus infection in a human lung organ culture model</article-title>. <source>Virology.</source> (<year>2010</year>) <volume>396</volume>:<fpage>178</fpage>&#x02013;<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.10.016</pub-id><?supplied-pmid 19913271?><pub-id pub-id-type="pmid">19913271</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado-Ortega</surname><given-names>M</given-names></name><name><surname>Melo</surname><given-names>S</given-names></name><name><surname>Punyadarsaniya</surname><given-names>D</given-names></name><name><surname>Rame</surname><given-names>C</given-names></name><name><surname>Olivier</surname><given-names>M</given-names></name><name><surname>Soubieux</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Innate immune response to a H3N2 subtype swine influenza virus in newborn porcine trachea cells, alveolar macrophages, and precision-cut lung slices</article-title>. <source>Vet Res.</source> (<year>2014</year>) <volume>45</volume>:<fpage>42</fpage>. <pub-id pub-id-type="doi">10.1186/1297-9716-45-42</pub-id><?supplied-pmid 24712747?><pub-id pub-id-type="pmid">24712747</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chokki</surname><given-names>M</given-names></name><name><surname>Yamamura</surname><given-names>S</given-names></name><name><surname>Eguchi</surname><given-names>H</given-names></name><name><surname>Masegi</surname><given-names>T</given-names></name><name><surname>Horiuchi</surname><given-names>H</given-names></name><name><surname>Tanabe</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Human airway trypsin-like protease increases mucin gene expression in airway epithelial cells</article-title>. <source>Am J Respir Cell Mol Biol.</source> (<year>2004</year>) <volume>30</volume>:<fpage>470</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2003-0199OC</pub-id><?supplied-pmid 14500256?><pub-id pub-id-type="pmid">14500256</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbier</surname><given-names>D</given-names></name><name><surname>Garcia-Verdugo</surname><given-names>I</given-names></name><name><surname>Pothlichet</surname><given-names>J</given-names></name><name><surname>Khazen</surname><given-names>R</given-names></name><name><surname>Descamps</surname><given-names>D</given-names></name><name><surname>Rousseau</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Influenza A induces the major secreted airway mucin MUC5AC in a protease-EG, FR-extracellular regulated kinase-Sp1-dependent pathway</article-title>. <source>Am J Respir Cell Mol Biol.</source> (<year>2012</year>) <volume>47</volume>:<fpage>149</fpage>&#x02013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1165/rcmb.2011-0405OC</pub-id><?supplied-pmid 22383584?><pub-id pub-id-type="pmid">22383584</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haga</surname><given-names>S</given-names></name><name><surname>Nagata</surname><given-names>N</given-names></name><name><surname>Okamura</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><name><surname>Sata</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds</article-title>. <source>Antiviral Res.</source> (<year>2010</year>) <volume>85</volume>:<fpage>551</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.antiviral.2009.12.001</pub-id><?supplied-pmid 19995578?><pub-id pub-id-type="pmid">19995578</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villeret</surname><given-names>B</given-names></name><name><surname>Dieu</surname><given-names>A</given-names></name><name><surname>Straube</surname><given-names>M</given-names></name><name><surname>Solhonne</surname><given-names>B</given-names></name><name><surname>Miklavc</surname><given-names>P</given-names></name><name><surname>Hamadi</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Silver nanoparticles impair retinoic acid-inducible gene i-mediated mitochondrial antiviral immunity by blocking the autophagic flux in lung epithelial cells</article-title>. <source>ACS Nano.</source> (<year>2018</year>) <volume>12</volume>:<fpage>1188</fpage>&#x02013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.7b06934</pub-id><?supplied-pmid 29357226?><pub-id pub-id-type="pmid">29357226</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Teoh</surname><given-names>KT</given-names></name><name><surname>Siu</surname><given-names>YL</given-names></name><name><surname>Chan</surname><given-names>WL</given-names></name><name><surname>Schluter</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>CJ</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><etal/></person-group>. <article-title>The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis</article-title>. <source>Mol Biol Cell.</source> (<year>2010</year>) <volume>21</volume>:<fpage>3838</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1091/mbc.e10-04-0338</pub-id><?supplied-pmid 20861307?><pub-id pub-id-type="pmid">20861307</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>M</given-names></name><name><surname>Hibbs</surname><given-names>ML</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name></person-group>. <article-title>The contributions of lung macrophage and monocyte heterogeneity to influenza pathogenesis</article-title>. <source>Immunol Cell Biol.</source> (<year>2017</year>) <volume>95</volume>:<fpage>225</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1038/icb.2016.97</pub-id><?supplied-pmid 27670791?><pub-id pub-id-type="pmid">27670791</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Ng</surname><given-names>IH</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Wu</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages <italic>in vitro</italic>: possible relevance to pathogenesis</article-title>. <source>J Virol.</source> (<year>2005</year>) <volume>79</volume>:<fpage>7819</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.12.7819-7826.2005</pub-id><?supplied-pmid 15919935?><pub-id pub-id-type="pmid">15919935</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>HK</given-names></name><name><surname>Cheung</surname><given-names>CY</given-names></name><name><surname>Ng</surname><given-names>HY</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chan</surname><given-names>YO</given-names></name><name><surname>Luk</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells</article-title>. <source>Blood.</source> (<year>2005</year>) <volume>106</volume>:<fpage>2366</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2004-10-4166</pub-id><?supplied-pmid 15860669?><pub-id pub-id-type="pmid">15860669</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dosch</surname><given-names>SF</given-names></name><name><surname>Mahajan</surname><given-names>SD</given-names></name><name><surname>Collins</surname><given-names>AR</given-names></name></person-group>. <article-title>SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages <italic>in vitro</italic></article-title>. <source>Virus Res.</source> (<year>2009</year>) <volume>142</volume>:<fpage>19</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.virusres.2009.01.005</pub-id><?supplied-pmid 19185596?><pub-id pub-id-type="pmid">19185596</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Qahtani</surname><given-names>AA</given-names></name><name><surname>Lyroni</surname><given-names>K</given-names></name><name><surname>Aznaourova</surname><given-names>M</given-names></name><name><surname>Tseliou</surname><given-names>M</given-names></name><name><surname>Al-Anazi</surname><given-names>MR</given-names></name><name><surname>Al-Ahdal</surname><given-names>MN</given-names></name><etal/></person-group>. <article-title>Middle east respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma</article-title>. <source>Oncotarget.</source> (<year>2017</year>) <volume>8</volume>:<fpage>9053</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.14754</pub-id><?supplied-pmid 28118607?><pub-id pub-id-type="pmid">28118607</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Whitmore</surname><given-names>A</given-names></name><name><surname>Agnihothram</surname><given-names>S</given-names></name><name><surname>Schafer</surname><given-names>A</given-names></name><name><surname>Katze</surname><given-names>MG</given-names></name><name><surname>Heise</surname><given-names>MT</given-names></name><etal/></person-group>. <article-title>Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection</article-title>. <source>MBio.</source> (<year>2015</year>) <volume>6</volume>:<fpage>e00638</fpage>&#x02013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1128/mBio.00638-15</pub-id><?supplied-pmid 26015500?><pub-id pub-id-type="pmid">26015500</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gralinski</surname><given-names>LE</given-names></name><name><surname>Menachery</surname><given-names>VD</given-names></name><name><surname>Morgan</surname><given-names>AP</given-names></name><name><surname>Totura</surname><given-names>AL</given-names></name><name><surname>Beall</surname><given-names>A</given-names></name><name><surname>Kocher</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Allelic variation in the toll-like receptor adaptor protein Ticam2 contributes to SARS-coronavirus pathogenesis in mice</article-title>. <source>G3.</source> (<year>2017</year>) <volume>7</volume>:<fpage>1653</fpage>&#x02013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1534/g3.117.041434</pub-id><?supplied-pmid 28592648?><pub-id pub-id-type="pmid">28592648</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>T</given-names></name><name><surname>Morrison</surname><given-names>TE</given-names></name><name><surname>Funkhouser</surname><given-names>W</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><etal/></person-group>
<article-title>MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV</article-title>. <source>PLoS Pathog.</source> (<year>2008</year>) <volume>4</volume>:<fpage>e1000240</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1000240</pub-id><pub-id pub-id-type="pmid">19079579</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>DN</given-names></name><name><surname>Pisetsky</surname><given-names>DS</given-names></name><name><surname>Schwartz</surname><given-names>DA</given-names></name></person-group>. <article-title>Toll-like receptors in the pathogenesis of human disease</article-title>. <source>Nat Immunol.</source> (<year>2004</year>) <volume>5</volume>:<fpage>975</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/ni1116</pub-id><?supplied-pmid 15454920?><pub-id pub-id-type="pmid">15454920</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Wan</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations</article-title>. <source>Cell Discov.</source> (<year>2020</year>) <volume>6</volume>:<fpage>11</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-020-0147-1</pub-id><?supplied-pmid 32133153?><pub-id pub-id-type="pmid">32133153</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>HK</given-names></name><name><surname>Huang</surname><given-names>SXL</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Kerner</surname><given-names>G</given-names></name><name><surname>Gilliaux</surname><given-names>O</given-names></name><name><surname>Bastard</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Severe influenza pneumonitis in children with inherited TLR3 deficiency</article-title>. <source>J Exp Med.</source> (<year>2019</year>) <volume>216</volume>:<fpage>2038</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20181621</pub-id><?supplied-pmid 31217193?><pub-id pub-id-type="pmid">31217193</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Channappanavar</surname><given-names>R</given-names></name><name><surname>Fehr</surname><given-names>AR</given-names></name><name><surname>Vijay</surname><given-names>R</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meyerholz</surname><given-names>DK</given-names></name><etal/></person-group>. <article-title>Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice</article-title>. <source>Cell Host Microbe.</source> (<year>2016</year>) <volume>19</volume>:<fpage>181</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><?supplied-pmid 26867177?><pub-id pub-id-type="pmid">26867177</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CT</given-names></name><name><surname>Fein</surname><given-names>AM</given-names></name><name><surname>Lippmann</surname><given-names>M</given-names></name><name><surname>Holtzman</surname><given-names>H</given-names></name><name><surname>Kimbel</surname><given-names>P</given-names></name><name><surname>Weinbaum</surname><given-names>G</given-names></name></person-group>. <article-title>Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome</article-title>. <source>N Engl J Med.</source> (<year>1981</year>) <volume>304</volume>:<fpage>192</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198101223040402</pub-id><?supplied-pmid 6969364?><pub-id pub-id-type="pmid">6969364</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aschner</surname><given-names>Y</given-names></name><name><surname>Zemans</surname><given-names>RL</given-names></name><name><surname>Yamashita</surname><given-names>CM</given-names></name><name><surname>Downey</surname><given-names>GP</given-names></name></person-group>. <article-title>Matrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDS</article-title>. <source>Chest.</source> (<year>2014</year>) <volume>146</volume>:<fpage>1081</fpage>&#x02013;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1378/chest.14-0397</pub-id><?supplied-pmid 25287998?><pub-id pub-id-type="pmid">25287998</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallenave</surname><given-names>JM</given-names></name><name><surname>Donnelly</surname><given-names>SC</given-names></name><name><surname>Grant</surname><given-names>IS</given-names></name><name><surname>Robertson</surname><given-names>C</given-names></name><name><surname>Gauldie</surname><given-names>J</given-names></name><name><surname>Haslett</surname><given-names>C</given-names></name></person-group>. <article-title>Secretory leukocyte proteinase inhibitor is preferentially increased in patients with acute respiratory distress syndrome</article-title>. <source>Eur Respir J.</source> (<year>1999</year>) <volume>13</volume>:<fpage>1029</fpage>&#x02013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.99.13510299</pub-id><?supplied-pmid 10414400?><pub-id pub-id-type="pmid">10414400</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kido</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>E</given-names></name><name><surname>Pan</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Role of host cellular proteases in the pathogenesis of influenza and influenza-induced multiple organ failure</article-title>. <source>Biochim Biophys Acta.</source> (<year>2012</year>) <volume>1824</volume>:<fpage>186</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbapap.2011.07.001</pub-id><?supplied-pmid 21801859?><pub-id pub-id-type="pmid">21801859</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talmi-Frank</surname><given-names>D</given-names></name><name><surname>Altboum</surname><given-names>Z</given-names></name><name><surname>Solomonov</surname><given-names>I</given-names></name><name><surname>Udi</surname><given-names>Y</given-names></name><name><surname>Jaitin</surname><given-names>DA</given-names></name><name><surname>Klepfish</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality</article-title>. <source>Cell Host Microbe.</source> (<year>2016</year>) <volume>20</volume>:<fpage>458</fpage>&#x02013;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.09.005</pub-id><?supplied-pmid 27736644?><pub-id pub-id-type="pmid">27736644</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villeret</surname><given-names>B</given-names></name><name><surname>Solhonne</surname><given-names>B</given-names></name><name><surname>Straube</surname><given-names>M</given-names></name><name><surname>Lemaire</surname><given-names>F</given-names></name><name><surname>Cazes</surname><given-names>A</given-names></name><name><surname>Garcia-Verdugo</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Influenza a virus pre-infection exacerbates <italic>Pseudomonas aeruginosa</italic>-mediated lung damage through increased MMP-9 expression, decreased elafin production and tissue resilience</article-title>. <source>Front Immunol.</source> (<year>2020</year>) <volume>11</volume>:<fpage>117</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.00117</pub-id><?supplied-pmid 32117268?><pub-id pub-id-type="pmid">32117268</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV</article-title>. <source>Emerg Microbes Infect.</source> (<year>2018</year>) <volume>7</volume>:<fpage>77</fpage>. <pub-id pub-id-type="doi">10.1038/s41426-018-0063-8</pub-id><?supplied-pmid 29691378?><pub-id pub-id-type="pmid">29691378</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delgado-Ortega</surname><given-names>M</given-names></name><name><surname>Marc</surname><given-names>D</given-names></name><name><surname>Dupont</surname><given-names>J</given-names></name><name><surname>Trapp</surname><given-names>S</given-names></name><name><surname>Berri</surname><given-names>M</given-names></name><name><surname>Meurens</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>SOCS proteins in infectious diseases of mammals</article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2013</year>) <volume>151</volume>:<fpage>1</fpage>&#x02013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2012.11.008</pub-id><?supplied-pmid 23219158?><pub-id pub-id-type="pmid">23219158</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pothlichet</surname><given-names>J</given-names></name><name><surname>Chignard</surname><given-names>M</given-names></name><name><surname>Si-Tahar</surname><given-names>M</given-names></name></person-group>. <article-title>Cutting edge: innate immune response triggered by influenza A virus is negatively regulated by SOCS1 and SOCS3 through a RIG-I/IFNAR1-dependent pathway</article-title>. <source>J Immunol.</source> (<year>2008</year>) <volume>180</volume>:<fpage>2034</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.180.4.2034</pub-id><?supplied-pmid 18250407?><pub-id pub-id-type="pmid">18250407</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kedzierski</surname><given-names>L</given-names></name><name><surname>Linossi</surname><given-names>EM</given-names></name><name><surname>Kolesnik</surname><given-names>TB</given-names></name><name><surname>Day</surname><given-names>EB</given-names></name><name><surname>Bird</surname><given-names>NL</given-names></name><name><surname>Kile</surname><given-names>BT</given-names></name><etal/></person-group>. <article-title>Suppressor of cytokine signaling 4 (SOCS4) protects against severe cytokine storm and enhances viral clearance during influenza infection</article-title>. <source>PLoS Pathog.</source> (<year>2014</year>) <volume>10</volume>:<fpage>e1004134</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004134</pub-id><?supplied-pmid 24809749?><pub-id pub-id-type="pmid">24809749</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caly</surname><given-names>L</given-names></name><name><surname>Druce</surname><given-names>JD</given-names></name><name><surname>Catton</surname><given-names>MG</given-names></name><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group>
<article-title>The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 <italic>in vitro</italic></article-title>. <source>Antiviral Res.</source> (<year>2020</year>) <volume>178</volume>:<fpage>104787</fpage>
<pub-id pub-id-type="doi">10.1016/j.antiviral.2020.104787</pub-id><pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrezenmeier</surname><given-names>E</given-names></name><name><surname>Dorner</surname><given-names>T</given-names></name></person-group>. <article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title>. <source>Nat Rev Rheumatol.</source> (<year>2020</year>) <volume>16</volume>:<fpage>155</fpage>&#x02013;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-020-0372-x</pub-id><?supplied-pmid 32034323?><pub-id pub-id-type="pmid">32034323</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercuro</surname><given-names>NJ</given-names></name><name><surname>Yen</surname><given-names>CF</given-names></name><name><surname>Shim</surname><given-names>DJ</given-names></name><name><surname>Maher</surname><given-names>TR</given-names></name><name><surname>McCoy</surname><given-names>CM</given-names></name><name><surname>Zimetbaum</surname><given-names>PJ</given-names></name><etal/></person-group>. <article-title>Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for Coronavirus Disease 2019 (COVID-19)</article-title>. <source>JAMA Cardiol.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1001/jamacardio.2020.1834</pub-id>. [Epub ahead of print].<?supplied-pmid 32356863?><pub-id pub-id-type="pmid">32356863</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amanat</surname><given-names>F</given-names></name><name><surname>Krammer</surname><given-names>F</given-names></name></person-group>. <article-title>SARS-CoV-2 vaccines: status report</article-title>. <source>Immunity.</source> (<year>2020</year>) <volume>52</volume>:<fpage>583</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2020.03.007</pub-id><?supplied-pmid 32259480?><pub-id pub-id-type="pmid">32259480</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Hillyer</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>L</given-names></name></person-group>. <article-title>Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses</article-title>. <source>Trends Immunol.</source> (<year>2020</year>) <volume>41</volume>:<fpage>355</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2020.03.007</pub-id><?supplied-pmid 32249063?><pub-id pub-id-type="pmid">32249063</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Rapid development of an inactivated vaccine candidate for SARS-CoV-2</article-title>. <source>Science.</source> (<year>2020</year>) eabc1932. <pub-id pub-id-type="doi">10.1126/science.abc1932</pub-id>. [Epub ahead of print].<?supplied-pmid 32376603?><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJW</given-names></name><name><surname>Moorlag</surname><given-names>S</given-names></name><name><surname>Novakovic</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>SY</given-names></name><name><surname>Oosting</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity</article-title>. <source>Cell Host Microbe.</source> (<year>2018</year>) <volume>23</volume>:<fpage>89</fpage>&#x02013;<lpage>100 e105</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2017.12.010</pub-id><?supplied-pmid 29324233?><pub-id pub-id-type="pmid">29324233</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Joosten</surname><given-names>LAB</given-names></name></person-group>. <article-title>Trained immunity and local innate immune memory in the lung</article-title>. <source>Cell.</source> (<year>2018</year>) <volume>175</volume>:<fpage>1463</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.11.007</pub-id><?supplied-pmid 30500533?><pub-id pub-id-type="pmid">30500533</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Jeyanathan</surname><given-names>M</given-names></name><name><surname>Haddadi</surname><given-names>S</given-names></name><name><surname>Barra</surname><given-names>NG</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><name><surname>Damjanovic</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Induction of autonomous memory alveolar macrophages requires t cell help and is critical to trained immunity</article-title>. <source>Cell.</source> (<year>2018</year>) <volume>175</volume>:<fpage>1634</fpage>&#x02013;<lpage>50 e1617</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2018.09.042</pub-id><?supplied-pmid 30433869?><pub-id pub-id-type="pmid">30433869</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iwata-Yoshikawa</surname><given-names>N</given-names></name><name><surname>Uda</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Tsunetsugu-Yokota</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Morikawa</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title>. <source>J Virol.</source> (<year>2014</year>) <volume>88</volume>:<fpage>8597</fpage>&#x02013;<lpage>614</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00983-14</pub-id><pub-id pub-id-type="pmid">24850731</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Covi&#x000e1;n</surname><given-names>C</given-names></name><name><surname>Retamal-D&#x000ed;az</surname><given-names>A</given-names></name><name><surname>Bueno</surname><given-names>SM</given-names></name><name><surname>Kalergis</surname><given-names>AM</given-names></name></person-group>
<article-title>Could BCG vaccination induce protective trained immunity for SARS-CoV-2?</article-title>
<source>Front Immunol.</source> (<year>2020</year>) <volume>11</volume>:<fpage>970</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2020.00970</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>Z</given-names></name><name><surname>Afkhami</surname><given-names>S</given-names></name><name><surname>Bavananthasivam</surname><given-names>J</given-names></name><name><surname>Fritz</surname><given-names>DK</given-names></name><name><surname>D'Agostino</surname><given-names>MR</given-names></name><name><surname>Vaseghi-Shanjani</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies</article-title>. <source>J Leukoc Biol.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1002/JLB.4MR0220-446R</pub-id>. [Epub ahead of print].<?supplied-pmid 32125045?><pub-id pub-id-type="pmid">32125045</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallenave</surname><given-names>JM</given-names></name><name><surname>Guillot</surname><given-names>L</given-names></name></person-group>
<article-title>Host signaling and proteolytic pathways in the resolution or the exacerbation of coronavirus (CoV-2) infection in COVID-19 disease: what therapeutic targets?</article-title> (<year>2020</year>) <pub-id pub-id-type="doi">10.31219/osf.io/rtfmx</pub-id></mixed-citation></ref></ref-list><glossary><def-list><title>Abbreviations</title><def-item><term>CoV</term><def><p>Coronavirus</p></def></def-item><def-item><term>SARS</term><def><p>Severe Acute Respiratory Syndrome</p></def></def-item><def-item><term>MERS</term><def><p>Middle east respiratory syndrome</p></def></def-item><def-item><term>ARDS</term><def><p>acute respiratory disease syndrome</p></def></def-item><def-item><term>HIV</term><def><p>human immunodeficiency virus</p></def></def-item><def-item><term>S</term><def><p>Spike</p></def></def-item><def-item><term>E</term><def><p>envelop</p></def></def-item><def-item><term>M</term><def><p>matrix</p></def></def-item><def-item><term>N</term><def><p>nucleocapsid</p></def></def-item><def-item><term>HA</term><def><p>hemagglutinin</p></def></def-item><def-item><term>ACE2</term><def><p>angiotensin-converting enzyme 2</p></def></def-item><def-item><term>DPP4</term><def><p>Dipeptidyl peptidase 4</p></def></def-item><def-item><term>TTSP</term><def><p>type II transmembrane serine proteases</p></def></def-item><def-item><term>TMPRSS</term><def><p>Transmembrane protease serine</p></def></def-item><def-item><term>NF-kB</term><def><p>Nuclear Factor</p></def></def-item><def-item><term>IL</term><def><p>interleukin</p></def></def-item><def-item><term>KO</term><def><p>knock-out</p></def></def-item><def-item><term>ATI</term><def><p>alveolar type I epithelial cell</p></def></def-item><def-item><term>ATII</term><def><p>alveolar type II epithelial cell</p></def></def-item><def-item><term>PRR</term><def><p>pattern recognition receptors</p></def></def-item><def-item><term>PAMPs</term><def><p>pathogen-associated molecular patterns</p></def></def-item><def-item><term>TLR</term><def><p>Toll-Like Receptors</p></def></def-item><def-item><term>IFN</term><def><p>interferon</p></def></def-item><def-item><term>Mac</term><def><p>macrophages</p></def></def-item><def-item><term>DCs</term><def><p>dendritic cells</p></def></def-item><def-item><term>PBMC</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>CCL2</term><def><p>C-C Motif Chemokine Ligand 2</p></def></def-item><def-item><term>C</term><def><p>ciliated</p></def></def-item><def-item><term>B</term><def><p>basal</p></def></def-item><def-item><term>G</term><def><p>glandular</p></def></def-item><def-item><term>CC</term><def><p>club cells</p></def></def-item><def-item><term>M</term><def><p>mucus</p></def></def-item><def-item><term>AM</term><def><p>alveolar macrophage</p></def></def-item><def-item><term>BCG</term><def><p>Bacille Calmette-Guerin.</p></def></def-item></def-list></glossary></back></article>